Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
These relationships are challenging to structure, and there’s often great pressure to conclude an agreement quickly and with modest cost.
You want to be sure your critical interests are protected, and to ensure that your contract can withstand future due diligence by potential investors, underwriters and commercial partners.
At Faber, we have an extensive practice devoted to collaborations between industry and academic institutions. Our 2000+ clients have included public and venture-backed companies, investors, academic researchers and entrepreneurs, foundations and other not-for-profit entities, and some of the most prestigious universities in the U.S. and Europe.
We regularly work with startups seeking to in-license their core technology, as well as more established companies looking for complementary discovery and development expertise. We have helped academic institutions negotiate intellectual property licenses, organize consortiums and optimize their investments in companies that are further developing technology invented in the institutions’ labs.
Our transactional experience includes:
We have more professionals focused on this area than you’re likely to find anywhere else, including lawyers and contracts specialists who have devoted their entire careers to these collaborations, and have worked in-house in these institutions. We recognize that the cultures of these institutions are unique, leading to profoundly different approaches to contracting. And we know how to navigate the negotiation in order to get the job done efficiently, without sacrificing important details. Based on our significant market knowledge, we can advise you on prioritizing goals in negotiations and efficiently finding common ground.
Faber assisted Ipsen with a Research and Option Agreement under which Université de Montréal would conduct a lead optimization program on a high-value oncology program. Upon exercise of the option at the end of the research term, Ipsen would acquire an exclusive license for the worldwide rights to the program
Strategic Licensing Agreement for Next-Generation Gene Therapy Technologies
Discovery Collaboration Focused on Generation of Stem Cell Lines to Enable Development of Novel Therapeutics for Neurodegenerative Diseases
Gene Therapy Alliance with Weill Cornell Medical through a series of 3 exclusive license agreements and a services agreement for research, development and commercialization of multiple AAV-based gene therapy indications
Exclusive license of clinical-stage T-cell therapy technology
Sale of Phenex’s FXR program for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases